How Long Does It Take to See Visible Results When Using Pyrilutamide Topically?

Pyrilutamide, also known by its developmental code KX-826, is one of the most discussed experimental compounds for androgenetic alopecia (pattern hair loss). It is being tested as a topical androgen receptor antagonist, designed to prevent dihydrotestosterone (DHT) from binding to hair follicle receptors. Unlike systemic treatments such as finasteride, which lowers overall DHT levels in the body, pyrilutamide is intended to act locally on the scalp. It is not an approved medicine anywhere, and it is not available on prescription.

That mechanism has made it an interesting prospect for people seeking a treatment that avoids hormonal side effects. The honest answer to "how long until I see results" is that nobody can say, because the published record consists of sponsor announcements measured at fixed trial timepoints, not observations of when individuals notice a change.

To interpret clinical results, it is essential to understand the biological process of hair growth. Hair follicles undergo a continuous cycle consisting of anagen (growth), catagen (transition), and telogen (resting or shedding) phases. Treatments targeting androgenetic alopecia generally work by prolonging the anagen phase and reversing follicular miniaturization caused by DHT. Since each follicle’s cycle spans months, any meaningful regrowth would be gradual. Pyrilutamide is designed to bind androgen receptors in the skin and hair follicles, blocking DHT from exerting its miniaturizing effects. Because this is intended to occur at the receptor level rather than systemically, the molecule is meant to reduce localized DHT activity without altering blood hormone concentrations. That is the design rationale, not a demonstrated result.

What the Clinical Research Actually Reports

The pyrilutamide programme is run by Kintor Pharmaceutical Ltd. and registered on ClinicalTrials.gov. It includes two Phase I studies in men with alopecia (NCT04502901 and NCT04984707, 40 participants each), a Phase II study in men in the United States (NCT05218642, 123 participants), a Phase II study in men (NCT05940506, 120 participants), a Phase II study in Chinese women (NCT06409650, 160 participants), a Phase III study in Chinese men (NCT06126965, 740 participants, registry status "unknown"), and an adaptive Phase II/III study in Chinese men (NCT06622824).

All of these trials measured their outcomes at fixed endpoints — the efficacy studies at 24 weeks — using standardized scalp photography and hair counts. That is the single most useful fact for anyone asking about timing: 24 weeks is where the data are, and no published trial reports at what week individual participants first noticed a difference.

In March 2026, Kintor announced top-line results from the Phase III stage of the adaptive trial: 666 patients across 26 centres in China over 24 weeks. The company reported that target-area non-vellus hair count rose by 15.33 hairs/cm² from baseline with a 1.0% tincture applied twice daily and 14.46 hairs/cm² with a 0.5% tincture, against 4.68 hairs/cm² for vehicle (P<0.0001), and that no drug-related serious adverse events were observed.

Every one of those figures comes from a company press release. None of the pyrilutamide efficacy data have appeared in a peer-reviewed journal, no independent group has replicated them, and reporting across earlier stages of the programme has been described as inconsistent. Industry-funded studies often require third-party verification to confirm claims and eliminate bias, and that verification has not happened here.

So, When Are Results Noticeable?

There is no published evidence that identifies a week at which users start to see a change. Anything circulating as an "8 to 12 week" figure for pyrilutamide is not from a trial report. What can be said is that the trials assessed their participants at 24 weeks, and that hair biology makes any earlier judgement unreliable: follicles need to re-enter the anagen phase and grow out thicker, pigmented hairs, which takes months regardless of the product.

Some users report an apparent increase in shedding during the first weeks of a new topical. This is described in the community for several hair-loss treatments, but it has not been documented in the published pyrilutamide record, and it should not be read as proof that a product is working. Increased shedding can also mean irritation, an unrelated cause of hair loss, or a reaction to whatever an unregulated product actually contains. If you notice a sudden increase in shedding, stop and speak to a doctor rather than assuming it is a good sign.

Evaluating the Evidence Critically

The research on pyrilutamide is incomplete. The available data come from sponsor-funded trials that have not appeared in peer-reviewed journals, and there is no head-to-head comparison against established treatments like minoxidil or finasteride, so its relative effectiveness is unknown.

Pyrilutamide has not received regulatory approval from the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or China's NMPA. Its safety and efficacy are experimental, and long-term safety data do not exist. Anyone obtaining the compound through unregulated research-chemical vendors should recognise that the concentration, the formulation stability, the purity, and even the identity of what is in the bottle have not been verified by anyone.

The Realistic Expectation

Set expectations against what exists: one set of unpublished company results measured at 24 weeks, in trials that selected and monitored their participants. Individual response would vary with genetic predisposition, follicle sensitivity, and consistency of use, and none of that has been characterised for this compound. It is reasonable to treat the current findings as preliminary, pending independent replication and regulatory review.

Talk to a doctor or pharmacist before starting, stopping or combining any hair-loss treatment, and before using any unapproved research compound — including pyrilutamide — particularly alongside prescription drugs such as finasteride or dutasteride. A dermatologist can confirm what is causing your hair loss and which approved treatments apply to it.

References

ClinicalTrials.gov. To Evaluate Efficacy, Safety, and Tolerability of KX-826 in Male Subjects With Androgenetic Alopecia (Phase II, 123 participants). NCT05218642. https://clinicaltrials.gov/study/NCT05218642

ClinicalTrials.gov. Phase II Study Evaluating the Efficacy and Safety of KX-826 (120 participants). NCT05940506. https://clinicaltrials.gov/study/NCT05940506

ClinicalTrials.gov. To Evaluate Safety and Efficacy of KX-826 in Chinese Female Subjects With Androgenetic Alopecia (Phase II, 160 participants). NCT06409650. https://clinicaltrials.gov/study/NCT06409650

ClinicalTrials.gov. Phase III Study of KX-826 With Adult Male Patients With AGA (740 participants). NCT06126965. https://clinicaltrials.gov/study/NCT06126965

Kintor Pharmaceutical. Phase III KX-826 Tincture 1.0% For AGA Reached Primary Endpoint (company announcement, 18 March 2026). https://en.kintor.com.cn/news_details/22.html